SEC Form 4 · accession 0001225208-18-012447
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A Mussallem
Officer — Chairman & CEO · Director
Period of report
Aug 7, 2018
Accepted (ET)
Aug 8, 2018 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2018 | M | 32,900 | $42.725 | A | 76,026 | D | |
| Common Stock | Aug 7, 2018 | S | 100 | $143.92 | D | 75,926 | D | |
| Common StockF2 | Aug 7, 2018 | S | 500 | $143.042 | D | 75,426 | D | |
| Common StockF3 | Aug 7, 2018 | S | 32,300 | $142.3546 | D | 43,126 | D | |
| Common Stock | holding | — | — | — | 123,931 | I | 401(k) | |
| Common Stock | holding | — | — | — | 745,400 | I | By Living Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Acquire) | $42.725 | Aug 7, 2018 | M | 32,900 | D | Jun 9, 2012 | May 8, 2019 | Common Stock | 32,900 | 221,100 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $142.90 to $143.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $141.83 to $142.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.